$AYTU
AYTU BIOPHARMA, INC Stock $aytu

$aytu Overview Financials Valuation SEC Filings Company Website

2015 Q2 Form 10-Q Financial Statement

#000119312515193527 Filed on May 19, 2015

Income Statement

Concept	2015 Q2	2015 Q1	2014 Q2
Revenue	$180.0K	$23.83K	$0.00
YoY Change		90.63%
Cost Of Revenue	$90.00K	$0.00
YoY Change
Gross Profit	$90.00K	$23.83K
YoY Change
Gross Profit Margin	50.0%	100.0%
Selling, General & Admin	$1.400M	$1.070M	$10.00K
YoY Change	13900.0%	5250.46%	0.0%
% of Gross Profit	1555.56%	4490.71%
Research & Development	$850.0K	$694.2K
YoY Change		-43.92%
% of Gross Profit	944.44%	2913.17%
Depreciation & Amortization	$50.00K	$0.00	$0.00
YoY Change
% of Gross Profit	55.56%	0.0%
Operating Expenses	$2.240M	$1.830M	$10.00K
YoY Change	22300.0%	47.83%	0.0%
Operating Profit	-$2.150M	-$1.806M
YoY Change
Interest Expense	$0.00	$36.05K	$0.00
YoY Change		200.93%
% of Operating Profit
Other Income/Expense, Net		-$36.05K	$0.00
YoY Change		200.93%
Pretax Income	-$2.160M	-$1.842M	-$10.00K
YoY Change	21500.0%	-8.03%	0.0%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$2.160M	-$1.842M	-$10.00K
YoY Change	21500.0%	9.63%	0.0%
Net Earnings / Revenue	-1200.0%	-7730.87%
Basic Earnings Per Share
Diluted Earnings Per Share	-$34.08B	-$988.9M	-$1.350B
COMMON SHARES
Basic Shares Outstanding	173.6M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q2	2015 Q1	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.400M	$0.00	$0.00
YoY Change
Cash & Equivalents	$7.353M	$1.491M	$2.640M
Short-Term Investments
Other Short-Term Assets	$500.0K	$0.00	$0.00
YoY Change
Inventory	$39.44K	$11.23K
Prepaid Expenses	$370.9K	$25.00K	$521.3K
Receivables	$157.1K	$1.036K
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$8.042M	$1.650M	$3.302M
YoY Change	143.57%
LONG-TERM ASSETS
Property, Plant & Equipment	$29.71K	$36.59K	$57.25K
YoY Change	-48.11%
Goodwill	$74.00K
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00	$0.00
YoY Change
Total Long-Term Assets	$10.14M	$8.551M	$8.714M
YoY Change	16.39%
TOTAL ASSETS
Total Short-Term Assets	$8.042M	$1.650M	$3.302M
Total Long-Term Assets	$10.14M	$8.551M	$8.714M
Total Assets	$18.19M	$10.20M	$12.02M
YoY Change	51.34%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.200M	$546.3K	$649.5K
YoY Change	84.76%
Accrued Expenses	$200.0K	$0.00	$0.00
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.478M	$9.203M	$6.092M
YoY Change	-75.75%	4501.44%	5992.28%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.100M	$400.0K
YoY Change
Total Long-Term Liabilities	$1.100M	$400.0K	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.478M	$9.203M	$6.092M
Total Long-Term Liabilities	$1.100M	$400.0K	$0.00
Total Liabilities	$2.569M	$9.650M	$6.647M
YoY Change	-61.35%	4725.1%	6546.69%
SHAREHOLDERS EQUITY
Retained Earnings	-$18.38M	-$12.61M	-$10.66M
YoY Change	72.47%
Common Stock	$39.00M	$13.16M	$16.03M
YoY Change	143.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$15.62M	$551.3K	$5.369M
YoY Change
Total Liabilities & Shareholders Equity	$18.19M	$10.20M	$12.02M
YoY Change	51.34%

Cashflow Statement

Concept	2015 Q2	2015 Q1	2014 Q2
OPERATING ACTIVITIES
Net Income	-$2.160M	-$1.842M	-$10.00K
YoY Change	21500.0%	9.63%	0.0%
Depreciation, Depletion And Amortization	$50.00K	$0.00	$0.00
YoY Change
Cash From Operating Activities	-$1.780M	-$10.00K	-$10.00K
YoY Change	17700.0%	0.0%	0.0%
INVESTING ACTIVITIES
Capital Expenditures	$0.00		$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$1.000M	$0.00
YoY Change
Cash From Investing Activities	-$1.000M	$0.00	$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	8.650M	0.000	30.00K
YoY Change	28733.33%		200.0%
NET CHANGE
Cash From Operating Activities	-1.780M	-10.00K	-10.00K
Cash From Investing Activities	-1.000M	0.000	0.000
Cash From Financing Activities	8.650M	0.000	30.00K
Net Change In Cash	5.870M	-10.00K	20.00K
YoY Change	29250.0%	0.0%
FREE CASH FLOW
Cash From Operating Activities	-$1.780M	-$10.00K	-$10.00K
Capital Expenditures	$0.00		$0.00
Free Cash Flow	-$1.780M		-$10.00K
YoY Change	17700.0%		0.0%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2013Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2913701
CY2014Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4121044
CY2014Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2014Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2014Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2014Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2014Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5369406
CY2014Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	511607
CY2014Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6092279
CY2014Q2	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	4300000
CY2014Q2	us-gaap	Common Stock Value CommonStockValue	4465
CY2014Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2014Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	649504
CY2014Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-7041839
CY2014Q2	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	55672
CY2014Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	12406780
CY2014Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	861059
CY2014Q2	us-gaap	Stockholders Equity StockholdersEquity	5369406
CY2014Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12028964
CY2014Q2	us-gaap	Due To Related Parties Current DueToRelatedPartiesCurrent	150000
CY2014Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	85714
CY2014Q2	us-gaap	Liabilities Liabilities	6659558
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2639650
CY2014Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57246
CY2014Q2	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	7500000
CY2014Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	699563
CY2014Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	8714247
CY2014Q2	us-gaap	Assets Assets	12028964
CY2014Q2	us-gaap	Deferred Tax Assets Net Current DeferredTaxAssetsNetCurrent	31762
CY2014Q2	us-gaap	Assets Current AssetsCurrent	3314717
CY2014Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	521322
CY2014Q2	rswn	Share Based Compensation Share Warrants Outstanding Weighted Average Exercise Price ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice	1.00
CY2014Q2	rswn	Interest Payable Related Parties Current InterestPayableRelatedPartiesCurrent	46002
CY2014Q2	rswn	Share Based Compensation Share Warrants Outstanding ShareBasedCompensationShareWarrantsOutstanding	465250	shares
CY2014Q2	rswn	Prepaid Research And Development Related Party PrepaidResearchAndDevelopmentRelatedParty	121983
CY2014Q2	rswn	Prepaid Research And Development Related Party Noncurrent PrepaidResearchAndDevelopmentRelatedPartyNoncurrent	457438
CY2015Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19435402	shares
CY2015Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	120000000	shares
CY2015Q1	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	10000000	shares
CY2015Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2015Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2015Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2015Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	551256
CY2015Q1	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	447321
CY2015Q1	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	334000
CY2015Q1	rswn	Prepaid Research And Development Related Party PrepaidResearchAndDevelopmentRelatedParty	121983
CY2015Q1	rswn	Prepaid Research And Development Related Party Noncurrent PrepaidResearchAndDevelopmentRelatedPartyNoncurrent	365950
CY2015Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	173597365	shares
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3729866
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	34360529	shares
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.11
	us-gaap	Licenses Revenue LicensesRevenue	37500
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4401277
CY2015Q1	us-gaap	Inventory Net InventoryNet	11233
CY2015Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1036
CY2015Q1	us-gaap	Assets Current AssetsCurrent	1650454
CY2015Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	25000
CY2015Q1	rswn	Share Based Compensation Share Warrants Outstanding Weighted Average Exercise Price ShareBasedCompensationShareWarrantsOutstandingWeightedAverageExercisePrice	1.00
CY2015Q1	rswn	Interest Payable Related Parties Current InterestPayableRelatedPartiesCurrent	3329
CY2015Q1	rswn	Share Based Compensation Share Warrants Outstanding ShareBasedCompensationShareWarrantsOutstanding	465250	shares
CY2015Q1	rswn	Accrued Compensation Current AccruedCompensationCurrent	98949
CY2015Q1	rswn	Number Of Stock Option Plans NumberOfStockOptionPlans	2	Stock_Plan
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-11662
CY2015Q1	us-gaap	Liabilities Current LiabilitiesCurrent	9202888
CY2015Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	8000000
CY2015Q1	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	334000
CY2015Q1	us-gaap	Common Stock Value CommonStockValue	4465
CY2015Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	546346
CY2015Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-12609799
CY2015Q1	us-gaap	Contractual Obligation ContractualObligation	1876000
CY2015Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	13156590
CY2015Q1	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	468550
CY2015Q1	us-gaap	Stockholders Equity StockholdersEquity	551256
CY2015Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10201465
CY2015Q1	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	334000
CY2015Q1	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	85714
CY2015Q1	us-gaap	Contractual Obligation Future Minimum Payments Due Remainder Of Fiscal Year ContractualObligationFutureMinimumPaymentsDueRemainderOfFiscalYear	540000
CY2015Q1	us-gaap	Liabilities Liabilities	9650209
CY2015Q1	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	0
CY2015Q1	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	334000
CY2015Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1491202
CY2015Q1	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	1998
CY2015Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	36591
CY2015Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	7500000
CY2015Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	646472
CY2015Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	8551011
CY2015Q1	us-gaap	Assets Assets	10201465
	us-gaap	Revenues Revenues	37500
	us-gaap	Net Income Loss NetIncomeLoss	-3852119
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-24000
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	348510
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	385000
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-549159
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	63596
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-37500
	us-gaap	Interest Expense InterestExpense	11662
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2640525
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1207343
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-549158
	us-gaap	Proceeds From Contributed Capital ProceedsFromContributedCapital	637209
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	12033
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	4937209
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	299469
	us-gaap	Costs And Expenses CostsAndExpenses	4427115
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	4300000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1715001
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	582899
	us-gaap	Share Based Compensation ShareBasedCompensation	385342
	rswn	Research And Development Related Party ResearchAndDevelopmentRelatedParty	71589
	rswn	Amortization Of Prepaid Research And Development Due To Related Parties AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties	5083
	rswn	Increase Decrease In Prepaid Research And Development Due To Related Parties IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties	-315000
	rswn	Issuance Of Common Stock In Exchange For Acquired Assets IssuanceOfCommonStockInExchangeForAcquiredAssets	6803356
	rswn	Prepaid Research And Development And Accrued Liability Related Parties Unpaid PrepaidResearchAndDevelopmentAndAccruedLiabilityRelatedPartiesUnpaid	300000
	dei	Document Type DocumentType	10-Q
	dei	Entity Registrant Name EntityRegistrantName	ROSEWIND CORP
	dei	Trading Symbol TradingSymbol	RSWN
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-4846450
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	On June 1, 2015, the Rosewind shareholders will vote on a reverse stock split of the Company’s common stock at a ratio of one new share for every 12.174 shares outstanding.
	us-gaap	Basis Of Accounting BasisOfAccounting	<div> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Note 1 – Basis of Presentation and Business</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Basis of Presentation</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> These unaudited financial statements represent the financial statements of Rosewind Corporation (“Rosewind” or “the Company”). Rosewind purchased Luoxis Diagnostics, Inc. (“Luoxis”) and Vyrix Pharmaceuticals, Inc. (“Vyrix”) on April 16, 2015 in a reverse triangular merger. Thus, the Rosewind financial statements presented in this form 10-Q are actually the combined financials of Luoxis and Vyrix for any periods prior to April 16, 2015. These unaudited financial statements should be read in conjunction with Rosewind’s Form 8-K filed April 22, 2015, which included all disclosures required by generally accepted accounting principles, see Note 10 for further details. In the opinion of management, these unaudited financial statements contain all adjustments necessary to present fairly the financial position of Rosewind and the results of operations and cash flows for the interim periods presented. The results of operations for the period ended March 31, 2015 are not necessarily indicative of expected operating results for the full year. The information presented throughout the document as of and for the period ended March 31, 2015 is unaudited. Rosewind’s activities have not generated significant revenue to date.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Liquidity Disclosure—Company Discusses Liquidity Issues but Believes Actions It Has Taken Will Enable It to Continue as a Going Concern over the Next Year</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> At March 31, 2015, Rosewind had cash and cash equivalents of $1,491,000, a working capital deficit of $7,522,000 and an accumulated deficit of $12,610,000. Additionally, we have not generated any material revenue to date and are not profitable, and have incurred losses in each year since our inception.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Management has taken several actions to ensure that the Company will continue as a going concern through June 30, 2016, including, obtaining a $4.0 million cash infusion from Ampio Pharmaceuticals, Inc. (“Ampio”) during April of 2015 and an additional $10 million commitment from Ampio which will be funded prior to April 15, 2016. As of April 16, 2015, the funding from Ampio was converted into equity of the Company. We intend to seek additional capital within the next 12 months to expand our clinical development activities for Zertane and RedoxSYS. In addition, we intend to evaluate the capital markets from time to time to determine when to raise additional capital in the form of equity, convertible debt or otherwise, depending on market conditions relative to our need for funds at such time, and we will seek to raise additional capital during the next 12 months, if at all, at such time as we conclude that such capital is available on terms that we consider to be in the best interests of us and our stockholders. Lastly, we have entered into numerous distribution agreements and we expect to generate revenue during 2015 and 2016 from sales of our RedoxSYS system. Management believes that these actions will enable Rosewind to continue as a going concern through June 30, 2016.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Newly Issued Accounting Pronouncements</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In January 2015, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2015-01, “Extraordinary and Unusual Items (Subtopic 225-20): Simplifying Income Statement Presentation by Eliminating the Concept of Extraordinary Items.” The purpose of this amendment is to eliminate the concept of extraordinary items. As a result, an entity will no longer be required to separately classify, present and disclose extraordinary events and transactions. The amendment is effective for annual reporting periods beginning after December 15, 2015 and subsequent interim periods with early application permitted. Management is currently assessing the impact the adoption of ASU 2015-01 will have on our financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In August 2014, the FASB issued ASU No. 2014-15, “Presentation of Financial Statements-Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern” (“ASU 2014-15”). ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. The amendments in this ASU are effective for reporting periods beginning after December 15, 2016, with early adoption permitted. Management is currently assessing the impact the adoption of ASU 2014-15 will have on our financial statements.</p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> In May 2014, the FASB issued ASU 2014-09 regarding ASC Topic 606, “Revenue from Contracts with Customers”. The standard provides principles for recognizing revenue for the transfer of promised goods or services to customers with the consideration to which the entity expects to be entitled in exchange for those goods or services. The guidance will be effective for annual reporting periods beginning after December 15, 2016. Early adoption is not permitted. We are currently evaluating the accounting, transition and disclosure requirements of the standard and cannot currently estimate the financial statement impact of adoption.</p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 1px 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px">  </p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; MARGIN-LEFT: 62px; WIDOWS: 1; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b>Business</b></p> <p style="MARGIN-BOTTOM: 0pt; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: 10pt 'Times New Roman'; WIDOWS: 1; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px"> Rosewind is a specialty healthcare company concentrating on developing and commercializing products for redox-modulated conditions with an initial focus on urological indications and related conditions. The Company is focused primarily on the urological disorders market, specifically sexual dysfunction and male infertility, and expects to seek expansion opportunities in other urological indications such as urological cancers. The Company maintains a focus on the RedoxSYS oxidation-reduction potential (“ORP”) system as we are focused on commercializing the RedoxSYS system into the global research market while developing numerous clinical applications for this potential first-in-class diagnostic device.</p> </div>
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	44652500	shares
	dei	Document Period End Date DocumentPeriodEndDate	2015-03-31
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--08-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Entity Central Index Key EntityCentralIndexKey	0001385818
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	749810
	us-gaap	Payments For Deposits PaymentsForDeposits	1998
	us-gaap	Licenses Revenue LicensesRevenue	64286
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	11233
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5591870
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-110900
	us-gaap	Revenues Revenues	79746
	us-gaap	Net Income Loss NetIncomeLoss	-5567960
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1036
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-496322
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	750000
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-23910
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	73746
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-64286
	us-gaap	Interest Expense InterestExpense	110900
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2418125
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-1148448
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-23910
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-42673
CY2013Q1	us-gaap	Payment For Management Fee PaymentForManagementFee	22000
CY2014Q1	us-gaap	Payment For Management Fee PaymentForManagementFee	22000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	3700000
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-392509
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	313000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1998
	us-gaap	Costs And Expenses CostsAndExpenses	5560716
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3700000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2986597
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-103158
	us-gaap	Share Based Compensation ShareBasedCompensation	749810
	rswn	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	98949
	rswn	Products And Services Revenue ProductsAndServicesRevenue	15460
	rswn	Research And Development Related Party ResearchAndDevelopmentRelatedParty	155994
	rswn	Amortization Of Prepaid Research And Development Due To Related Parties AmortizationOfPrepaidResearchAndDevelopmentDueToRelatedParties	91488
	rswn	Increase Decrease In Prepaid Research And Development Due To Related Parties IncreaseDecreaseInPrepaidResearchAndDevelopmentDueToRelatedParties	-150000
	rswn	Class Of Warrant Or Rights Weighted Average Remaining Contractual Term ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm	P3Y2M1D
CY2014	rswn	Class Of Warrant Or Rights Weighted Average Remaining Contractual Term ClassOfWarrantOrRightsWeightedAverageRemainingContractualTerm	P3Y11M1D
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	44652500	shares
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2014Q1	us-gaap	Licenses Revenue LicensesRevenue	12500
CY2015Q1	us-gaap	Interest Expense InterestExpense	36052
CY2015Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	694180
CY2015Q1	us-gaap	Costs And Expenses CostsAndExpenses	1829966
CY2015Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1087788
CY2015Q1	rswn	Products And Services Revenue ProductsAndServicesRevenue	2400
CY2015Q1	rswn	Research And Development Related Party ResearchAndDevelopmentRelatedParty	47998
CY2014Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-2002946
CY2014Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-11980
CY2014Q1	us-gaap	Revenues Revenues	12500
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-1680377
CY2014Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	84000
CY2014Q1	us-gaap	Interest Expense InterestExpense	11980
CY2014Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1237854
CY2014Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-322569
CY2014Q1	us-gaap	Costs And Expenses CostsAndExpenses	2003466
CY2014Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	737027
CY2014Q1	rswn	Research And Development Related Party ResearchAndDevelopmentRelatedParty	28585
CY2015Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	44652500	shares
CY2015Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2015Q1	us-gaap	Licenses Revenue LicensesRevenue	21429
CY2015Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1842189
CY2015Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-36052
CY2015Q1	us-gaap	Revenues Revenues	23829
CY2015Q1	us-gaap	Net Income Loss NetIncomeLoss	-1842189
CY2015Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	272000

Files In Submission

Name	View Source	Status
0001193125-15-193527-index-headers.html	Edgar Link	pending
0001193125-15-193527-index.html	Edgar Link	pending
0001193125-15-193527.txt	Edgar Link	pending
0001193125-15-193527-xbrl.zip	Edgar Link	pending
d922847d10q.htm	Edgar Link	pending
d922847dex311.htm	Edgar Link	pending
d922847dex312.htm	Edgar Link	pending
d922847dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
rswn-20150331.xml	Edgar Link	completed
rswn-20150331.xsd	Edgar Link	pending
rswn-20150331_cal.xml	Edgar Link	unprocessable
rswn-20150331_def.xml	Edgar Link	unprocessable
rswn-20150331_lab.xml	Edgar Link	unprocessable
rswn-20150331_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AYTU
AYTU BIOPHARMA, INC Stock $aytu

2015 Q2 Form 10-Q Financial Statement

#000119312515193527 Filed on May 19, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AYTU AYTU BIOPHARMA, INC Stock $aytu

2015 Q2 Form 10-Q Financial Statement

#000119312515193527 Filed on May 19, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AYTU
AYTU BIOPHARMA, INC Stock $aytu